DNA/Gene Microarray Market To Surpass US$ 9.91 Bn By 2030

Global DNA/Gene Microarray Market, By Type [Oligonucleotide DNA Microarrays and Complementary DNA Microarrays], By Application [Genomics, Proteomics, Agricultural Biology, Environment, Drug Research and Development, Cancer/oncology and Others (SNP Analysis, etc.)], By End User [Biopharmaceutical and Pharmaceutical Companies, Diagnostic Laboratories, Research Laboratories and Others(Academic Institutes, etc.)], and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4.24 Billion in 2023 and is expected to exhibit a CAGR of 12.9% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.

Key market players are focusing on adopting various growth strategies, such as agreemnet and others, which will drive the global DNA/Gene microarray market. For instance, in April 2020, Agilent Technologies Inc., a global life science compnay and SomaLogic, Inc., a privately held biotechnology company,  announced a multi-year supply agreement under which Agilent Technologies Inc. will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic's novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.

Global DNA/Gene Microarray Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the demand and supply in global DNA/gene microarray market. The COVID-19 pandemic has affected demand and supply of the global DNA/gene microarray market in three main ways: by directly affecting production and demand; by creating disruptions in distribution channels; and by having a financial impact on firms and financial markets. The supply chain and manufacturing activities of viral conjunctivitis drugs in India, China, and the U.S. are disrupted due to nationwide lockdowns. Whereas countries such as Saudi Arabia, the UAE, Egypt, and others are facing problems with regards to the transportation of drugs from one place to another.

COVID-19 had a positive impact on the global DNA/gene microarray market, as researchers were focused on developing SARS-CoV-2 variant protein microarrays for profiling humoral immunity in vaccinated patients. For instance, in March 2022, according to the report published in the National Center for Biotechnology information, the use of a protein microarray platform to evaluate the efficacy of an inactivated virus vaccine against different variants of SARS-CoV-2 was reported. The report also stated that this platform was highly effective for profiling humoral immunity by immobilizing multiple agents.

Global DNA/Gene Microarray Market: Key Developments

In July 2022, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of Illumina DRAGEN v4.0, an accurate and comprehensive secondary analysis platform that expands laboratories abilities to perform analyses in key areas such as oncology, pharmacogenomics (PGx), single-cell sequencing, and population genomics within a single platform. Small molecule for the treatment of severe eye diseases with a high unmet medical need.

In February 2020, Twist Bioscience Corporation, a biotechnology company, announced the launch of Twist Targeted Methylation Sequencing Solution to study methylation pattern changes in a wide range of research fields, including cancer. The Twist Targeted Methylation Sequencing Protocol uses the Fast Hybridization Target Enrichment workflow to generate target-enriched DNA libraries for sequencing on Illumina next-generation sequencing (NGS) systems.

Browse 46 Market Data Tables and 34 Figures spread through 170 Pages and in-depth TOC on “Global DNA/Gene Microarray Market”- Forecast to 2030, Global DNA/Gene Microarray Market, By Type [Oligonucleotide DNA Microarrays and Complementary DNA Microarrays], By Application [Genomics, Proteomics, Agricultural Biology, Environment, Drug Research and Development, Cancer/oncology and Others (SNP Analysis, etc.)], By End User [Biopharmaceutical and Pharmaceutical Companies, Diagnostic Laboratories, Research Laboratories and Others(Academic Institutes, etc.)], and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/dna-gene-microarray-market-3825

Key Takeaways of the Global DNA/Gene Microarray Market:

• The global DNA/gene microarray market is expected to exhibit a CAGR of 9% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global DNA/gene microarray market.
• Among application, genomics segment is expected to hold a dominant position in the global DNA/Gene microarray market during the forecast period and this is attributed to increasing research and development activities, which may help in market growth over the forecast period. For instance, in April 2020, researchers from the National Defense Medical Center, Taiwan, reported the use of DNA microarray gene expression profiles in research to assess the immunofunctionomes of ovarian clear cell carcinoma in early and advanced stages.
• Among regions, North America is expected to be the dominant region in the global DNA/gene microarray market, owing to the increasing adoption of inorganic growth strategies such as collaboration and others by the market players. For instance, in April 2020, Sio Gene Therapies, a biotechnology company based in the U.S. and North America, collaborated with Invitae Corporation, a provider of advanced medical genetics, to offer free genetic testing in the U.S. and Canada for pediatric lysosomal storage disease.
• Major players operating in the global DNA/gene microarray market are Affymetrix, Inc., Illumina, Inc., Agilent Technologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix Technology Inc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC, Microarrays Inc., Thermo Fisher Scientific Inc. , Bio-Rad Laboratories, Inc., Caliper Life Sciences, Perkin Elmer, Inc., PathogenDx, Inc., Twist Bioscience Corporation, Arraylt Corporation, Molecular Device, LLC and Raybiotech Inc.